NasdaqGM:VCYTBiotechs
Will New Clinical Evidence and Trial Progress Expand Veracyte's (VCYT) Role in Precision Oncology?
In late August 2025, Veracyte and University College London announced in Cell that the Decipher Prostate Genomic Classifier can predict which metastatic prostate cancer patients will benefit from docetaxel chemotherapy, while Veracyte also achieved full enrollment in its nightINGALE trial for the Percepta Nasal Swab lung cancer test.
These developments highlight Veracyte’s ongoing efforts to personalize cancer treatment decisions and expand the clinical utility of its genomic diagnostic...